Stock Market Reviews

GSK (GSK plc) News

Get the latest news, insights, and market updates on GSK (GSK plc). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Alector Stock Plummets 63% in a Month: Here's What You Need to Know
  ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
  Nov 18, 2025 - $GSK
• [Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)
  [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.
  Nov 18, 2025 - $GSK
• Renal Anemia Market Research Report 2025-2035, Competitive Analysis of Amgen, Sandoz, Pfizer, GlaxoSmithKline, Akebia Therapeutics, and Astellas Pharma
  The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe, and emerging markets. The market is reshaped by the expansion of erythropoiesis-stimulating agents (ESAs), iron supplements, and novel oral hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). Rising awareness about untreated renal anemia complications, such as fatigue, fuels the dem
  Nov 18, 2025 - $GSK
• GSK (GSK) is a Top-Ranked Momentum Stock: Should You Buy?
  Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
  Nov 17, 2025 - $GSK
• GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
  Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
  Nov 14, 2025 - $GSK
• Why GSK (GSK) is a Top Growth Stock for the Long-Term
  Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
  Nov 13, 2025 - $GSK
• GSK (LSE:GSK): Evaluating Valuation Following a Strong 12% One-Month Share Price Climb
  GSK (LSE:GSK) shares have edged slightly lower as investors digest recent trading activity and look for new signals on the company’s next move. Over the past month, the stock has delivered a 12% gain, outpacing many in its sector. See our latest analysis for GSK. Momentum has clearly picked up for GSK this year. The recent 12% 1-month share price return adds to strong gains since January. Over the longer term, total shareholder return stands at an impressive 41% for the past twelve months and...
  Nov 13, 2025 - $GSK
• Deutsche Bank Maintains a Hold Rating on GSK plc (GSK)
  GSK plc (NYSE:GSK) is one of the best undervalued stocks to buy under $50. Deutsche Bank analyst Emmanuel Papadakis released a rating update for GSK plc (NYSE:GSK), maintaining a Hold rating on the stock with a £16 price target on November 4. GSK plc (NYSE:GSK) recently released its fiscal Q3 earnings on October 29, reporting […]
  Nov 12, 2025 - $GSK
• Traders Anticipate Federal Government Reopening, Driving Premarket Gains for US Equity Futures
  US equity futures were up ahead of Wednesday's opening bell as traders monitored a potential resolut
  Nov 12, 2025 - $GSK
• Evaluating GSK's 34% Rise as Pipeline Progress Sparks New Valuation Debate
  Wondering if GSK is actually undervalued or if there's more to the story than recent headlines suggest? You're not alone, and we're about to dive into what those numbers really mean. Despite a slight dip of 0.7% in the last week, GSK shares have surged 9.1% over the past month and are up 34.0% over the last year, adding plenty of fuel to the "value" vs. "momentum" debate. Much of the recent price movement follows news of GSK's progress in its pharmaceuticals pipeline and strategic moves in...
  Nov 8, 2025 - $GSK